Amycretin mastery course
Unit 4 of 12

How amycretin works

Amycretin's weight-loss effect converges on the brain's appetite-control centers, especially the area postrema, a…

Two arms, one brainstem target

Amycretin's weight-loss effect converges on the brain's appetite-control centers, especially the area postrema, a brainstem region that senses hormones directly from the blood. Both its GLP-1 and amylin arms reach this satiety circuitry, and amylin also acts in parts of the hypothalamus, partly independently of the area postrema.

This unit traces the signal from receptor to behavior, shows where it acts in the brain and body, and explains why engaging two receptors at once should recruit a broader satiety network than either alone.

Key terms

Where the signal starts

The area postrema sits at the base of the brainstem and has an unusual property: its blood-brain barrier is leaky, so it can directly sense hormones circulating in the blood. Amylin receptors are co-expressed there, which makes it a frontline satiety sensor. No source this course uses reports a GLP-1 receptor density for it.

From receptor to reduced eating

What the published record actually establishes here is narrower than the diagram suggests, and worth stating precisely. Amylin acts at receptors co-expressed in the area postrema in the caudal hindbrain and in parts of the hypothalamus, and a fluorescent tracer study of amycretin itself found signal in four circumventricular organs: the area postrema, the median eminence, the vascular organ of the lamina terminalis and the subfornical organ. That is where the molecule reaches, in rodents. Which of those sites carries the human effect, and how much each arm contributes, is not established.

AdvancedWhy a leaky barrier lets a big peptide act centrally

Most of the brain is shielded from blood-borne peptides by the blood-brain barrier, so a large peptide like amycretin cannot simply diffuse in everywhere. The area postrema is a circumventricular organ with leaky capillaries, so it samples the blood directly. That anatomical quirk is why a big, albumin-bound peptide can still act centrally: it does not need to cross the barrier, it acts where the barrier is already open.


Where amycretin acts in the brain


Two arms converging


Slowing the stomach and glucose


The body-wide picture